Donafenib in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is a global healthcare problem, with a high prevalence in nonindustrialized countries and a rising incidence in industrialized coun-tries. Sorafenib demonstrated its efficacy as the first therapeutic agent for unresectable HCC in 2007. Since then, other multitarget tyrosine kinase inhibitors have demonstrated efficacy in HCC patients. Still, the tolerabilityofthesedrugsremainsan unsolved problem, with 5-20% of patients permanently discontinuing their therapies due to adverse events. Donafenib is a deu-terated form of sorafenib exploiting the increased bio-availability derived from the deuterium-for-hydrogen replacement. In the multicenter, randomized, contro-lled phase II-III trial ZGDH3, donafenib outperformed sorafenib in terms of overall survival, with favorable safety and tolerability. As a result, donafenib was approved as a possible first-line treatment of unresec-table HCC by the National Medical Products Adminis-tration (NMPA) of China in 2021. In this monograph, we review the main preclinical and clinical evidence that emerged in the trials of donafenib.

Automated summary

Hepatocellular carcinoma (HCC) is a global healthcare problem, with a high prevalence in nonindustrialized countries and a rising incidence in industrialized countries. Sorafenib, the first therapeutic agent for unresectable HCC, demonstrated efficacy in 2007. However, the tolerability of these drugs remains an unresolved issue. Donafenib, a deuterated form of sorafenib, has shown better overall survival and favorable safety and tolerability in a clinical trial, leading to its approval as a possible first-line treatment for unresectable HCC by the National Medical Products Administration of China in 2021.